Raymond James Financial Inc. Buys Shares of 47,863 Twist Bioscience Co. (NASDAQ:TWST)

Raymond James Financial Inc. purchased a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 47,863 shares of the company's stock, valued at approximately $2,224,000. Raymond James Financial Inc. owned about 0.08% of Twist Bioscience at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Van ECK Associates Corp increased its position in shares of Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after purchasing an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter worth approximately $34,000. US Bancorp DE lifted its stake in Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after buying an additional 601 shares during the last quarter. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the third quarter valued at approximately $95,000. Finally, KBC Group NV boosted its holdings in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after acquiring an additional 1,226 shares during the period.

Twist Bioscience Stock Performance

NASDAQ TWST traded down $0.71 on Thursday, hitting $37.50. 1,760,559 shares of the company's stock were exchanged, compared to its average volume of 949,035. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The firm's 50-day moving average price is $44.16 and its two-hundred day moving average price is $45.17. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -11.09 and a beta of 2.34. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Remove Ads

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the prior year, the company posted ($0.75) earnings per share. Twist Bioscience's quarterly revenue was up 24.1% on a year-over-year basis. On average, research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TWST shares. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Robert W. Baird boosted their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $54.10.

Insider Activity

In other Twist Bioscience news, Director Robert Chess sold 5,000 shares of the company's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the transaction, the director now directly owns 16,641 shares in the company, valued at approximately $832,050. This represents a 23.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Paula Green sold 1,259 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65. Following the sale, the senior vice president now owns 132,014 shares of the company's stock, valued at approximately $6,514,890.90. The trade was a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,799 shares of company stock worth $1,593,944 in the last 90 days. 3.01% of the stock is currently owned by corporate insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.